Child Development Disorders, Pervasive Clinical Trial
Official title:
Assessing Suicide Risk in Adolescents With Developmental Delays: Development of a Screening Tool
Background:
- Currently, there is no standard method to study suicide risk in youth with developmental
delays or intellectual disabilities (DD/ID). Youth with DD/ID are often excluded from studies
that are used to develop these methods. As a result, most current suicide risk assessments
have not been tested for use with people with DD/ID. Researchers want to develop an effective
suicide risk screening tool for children and adolescents with DD/ID.
Objectives:
- To develop a suicide risk screening tool for young adults with DD/ID.
Eligibility:
- Young adults between 12 and 21 years of age who have DD/ID and are in mental health
counseling.
- Participants will be in counseling at Surrey Place Centre, a community health center in
Toronto, Canada.
Design:
- Participants will fill out questionnaires during a 1-hour meeting with a therapist. The
questions will ask about mood and current feelings, including whether the participant
has been thinking about or planning to hurt or kill him or herself now or in the past.
Other questions will ask about participants' understanding of death in general.
- Parents of participants may also fill out a questionnaire. It will ask about how the
participant has been feeling. It will also ask whether the parent has noticed any signs
that suggest suicidal thoughts or actions, now and in the past.
- Treatment will not be provided as part of this protocol. However, participants can
receive counseling through the regular Surrey Place Centre services.
Objective:
Currently, no gold standard is available for evaluating suicidal thoughts and behaviors in
individuals with developmental delay or intellectual disabilities (DD/ID). Moreover, youth
with DD are often excluded from instrument validation studies. Therefore, there is a paucity
of sufficiently adapted and validated clinical suicide risk assessments for use with clients
with DD/ID. The main objective of this study is to develop and assess the efficacy of a
suicide screening tool for child and adolescent clients with DD/ID. More specifically:
Aim 1: To modify the Risk of Suicide Questionnaire (RSQ) in order to create a suicide
screening tool for a pediatric mental health population with DD/ID.
Aim 2: To determine the feasibility of a suicide screening tool, (developed in Aim 1) to
detect suicide risk in pediatric clients with DD/ID presenting to a community health center
for mental health reasons.
Study population:
The NIMH is collaborating with Surrey Place Centre, a community health center in Toronto,
Canada. The study population will be Surrey Place Centre clients, ages 12 and older,
diagnosed with DD/ID, currently accessing individual mental health counseling. There will be
no exclusion based on gender or race.
Design:
This will be a prospective instrument development study. Potential participants will be
identified by research assistants (RAs) and therapists. Following informed consent and assent
procedures, therapists will administer the Risk of Suicide Questionnaire Intellectual
Disability Patient (RSQ-ID-Patient), and the Suicidal Ideation Questionnaire Child Version
(SIQ-CV) to clients, and the RA will have the parents/guardians complete the Risk of Suicide
Questionnaire-Intellectual Disability-Parent (RSQ-ID Parent). Three months after client
participation, therapists will fill out a Therapist Follow-up Questionnaire.
Outcome measures:
Primary outcome measures include the RSQ-ID Patient, and the SIQ-CV, along with the RSQ-ID
Parent. Secondary outcome measure is the Research Assistant Evaluation Form and the Clinician
Follow- up Form.
;
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT03222375 -
SQUEDâ„¢ Series 28.1 Home-use and Treatment of Autowave Reverberator of Autism
|
N/A | |
Completed |
NCT01233414 -
Randomized Trial of Parent Training for Young Children With Autism
|
N/A | |
Completed |
NCT00926471 -
Social Skills and Anxiety Reduction Treatment for Children and Adolescents With Autism Spectrum Disorders
|
Phase 1 | |
Withdrawn |
NCT00376194 -
Mercury Chelation to Treat Autism
|
Phase 2 | |
Completed |
NCT02153203 -
Using the Prevent-Teach-Reinforce Model to Reduce Problem Behaviors in Children With Autism Spectrum Disorders
|
N/A | |
Completed |
NCT02301195 -
Trial of Therapeutic Horseback Riding in Children and Adolescents With Autism Spectrum Disorder
|
N/A | |
Completed |
NCT00453180 -
A Study of Oral N-Acetylcysteine in Children With Autism Spectrum Disorders
|
Phase 2 | |
Completed |
NCT04475848 -
A Study to Investigate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Food Effect of RO6953958 in Healthy Participants
|
Phase 1 | |
Completed |
NCT00080145 -
RUPP PI PDD: Drug and Behavioral Therapy for Children With Pervasive Developmental Disorders
|
N/A | |
Completed |
NCT00166595 -
Pharmacogenetics of Risperidone in Children With Pervasive Developmental Disorder (PDD)
|
Phase 1/Phase 2 | |
Completed |
NCT02124720 -
Using Mobile Technology to Reduce Stereotypy
|
N/A | |
Completed |
NCT01731119 -
Study of Lurasidone in Treating Antipsychotic Naive or Quasi-Naive Children and Adolescents
|
Phase 2 | |
Completed |
NCT00147394 -
Risperidone Pharmacokinetics in Children With Pervasive Developmental Disorder (PDD)
|
Phase 1 | |
Completed |
NCT01921244 -
Shared Decision Making to Improve Care and Outcomes for Children With Autism
|
N/A | |
Completed |
NCT05688319 -
Effect of Problem-Solving Training
|
N/A | |
Terminated |
NCT00445471 -
A Prospective Study Comparing the Mifne Approach of Treating Childhood Autism With Routine Standard Treatment
|
N/A | |
Active, not recruiting |
NCT00110708 -
Safety and Efficacy Study in the Treatment of Intestinal Problems Associated With Autism
|
Phase 2 |